Table 2 Changes in study outcome measures according to cardiac magnetic resonance imaging, mean ± SD and median (Q3–Q1)
|  | Control (n = 25) | Intervention (n = 20) | Repeated intervention (n = 20) | P value |
|---|---|---|---|---|
EF baseline | 40.33 ± 7.38 41 (47–35) | 40.5 ± 6.35 42.5 (46–33) | 39.5 ± 5.75 41.5 (45–32) | 0.392a |
EF final | 43.03 ± 7.5 43.6 (47.2–38.3) | 47.74 ± 9.87 51.2 (55.6–36.5) | 49.74 ± 10.12 53.2 (57.6–38.5) | 0.003a |
EF change | 2.69 ± 8.96 4.7 (9.7–(− 1.6)) | 7.24 ± 4.78 8.1 (11.9–1.7) | 10.24 ± 5.87 11.1 (14.9–4.7) | 0.001a |
LVEDV baseline | 184.5 ± 13.28 184.5 (196–173) | 177 ± 30.57 177 (206–148) | 181 ± 31.27 181 (210–152) | 0.274a |
LVEDV final | 231 ± 12.73 231 (.–222) | 140.8 ± 9.26 142 (149.5–131.5) | 137 ± 5.83 137 (142–132) | 0.53b |
LVEDV change | 58 ± 12.73 58 (.–49) | − 7.2 ± 9.26 − 6 (1.5–(− 16.51)) | − 15 ± 5.83 − 15 (− 10–(− 20)) | 0.175b |
LVESV baseline | 113.93 ± 029 113.9 (114.2–113.7) | 95.58 ± 16.51 95.6 (111.2–79.9) | 99.55 ± 16.81 99.6 (115.5–83.6) | 0.023a |
LVESV final | 133.98 ± 7.4 133.9 (.–128.8) | 60.54 ± 3.98 61.1 (64.3–56.6) | 56.17 ± 2.39 56.2 (58.2–54.1) | 0.076b |
LVESV change | 19.8 ± 7.38 19.8 (. –14.6) | − 19.38 ± 3.9 − 18.9 (− 15.6–(− 23.4) | − 27.43 ± 2.4 − 27.4 (− 25.4–(−29.5)) | 0.016b |